

# TNF $\alpha$ -mediated priming of mesenchymal stem cells enhances their neuroprotective effect on retinal ganglion cells

Mead, Ben; Chalming, Xitiz; Zack, Donald; Ahmed, Zubair; Tomarev, Stanislav

DOI:

[10.1167/iovs.61.2.6](https://doi.org/10.1167/iovs.61.2.6)

License:

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Mead, B, Chalming, X, Zack, D, Ahmed, Z & Tomarev, S 2020, 'TNF $\alpha$ -mediated priming of mesenchymal stem cells enhances their neuroprotective effect on retinal ganglion cells', *Investigative Ophthalmology & Visual Science (IOVS)*, vol. 61, no. 2, 6. <https://doi.org/10.1167/iovs.61.2.6>

[Link to publication on Research at Birmingham portal](#)

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# TNF $\alpha$ -Mediated Priming of Mesenchymal Stem Cells Enhances Their Neuroprotective Effect on Retinal Ganglion Cells

Ben Mead,<sup>1,2,3</sup> Xitiz Chamling,<sup>4</sup> Donald J. Zack,<sup>4</sup> Zubair Ahmed,<sup>2</sup> and Stanislav Tomarev<sup>3</sup>

<sup>1</sup>School of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom

<sup>2</sup>Neuroscience and Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom

<sup>3</sup>Section of Retinal Ganglion Cell Biology, Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States

<sup>4</sup>Wilmer Eye Institute, Departments of Ophthalmology, Molecular Biology and Genetics, Neuroscience, and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Correspondence: Ben Mead, School of Optometry and Vision Sciences, Cardiff University, Maindy Road, Cardiff CF24 4HQ, UK; [ben\\_mead@hotmail.com](mailto:ben_mead@hotmail.com), [meadb@cardiff.ac.uk](mailto:meadb@cardiff.ac.uk).

ZA and ST are joint senior authors.

**Received:** September 11, 2019

**Accepted:** November 14, 2019

**Published:** February 7, 2020

Citation: Mead B, Chamling X, Zack DJ, Ahmed Z, Tomarev S.

TNF $\alpha$ -mediated priming of mesenchymal stem cells enhances their neuroprotective effect on retinal ganglion cells. *Invest Ophthalmol Vis Sci.* 2020;61(2):6. <https://doi.org/10.1167/iov.61.2.6>

**PURPOSE.** To determine whether priming of bone marrow mesenchymal stem cells (MSCs) by signals from injured retina, particularly tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), increase their exosomes' neuroprotective efficacy on retinal ganglion cells (RGCs).

**METHODS.** MSCs were primed with retinal cell culture conditioned medium, with or without the TNF $\alpha$  blocker etanercept or TNF $\alpha$  prior to isolation of exosomes. MSC conditioned medium or exosomes were added to rat retinal cultures or human stem cell-derived retinal ganglion cell (hRGC) cultures, and RGC neuroprotective effects were quantified. Luminex assays were used to compare primed versus unprimed exosomes.

**RESULTS.** MSC conditioned medium and exosomes exerted a significant neuroprotective effect on injured rat and hRGC. This effect was significantly increased after MSCs were primed with retinal conditioned medium or TNF $\alpha$ . Blocking of TNF $\alpha$  signaling with etanercept prevented priming-induced RGC neuroprotective efficacy. Priming increased Pigment epithelium-derived factor (PEDF) and VEGF-AA exosomal abundance.

**CONCLUSIONS.** MSC exosomes promote RGC survival not just in rodent retinal cultures but also with hRGC. Their efficacy can be further enhanced through TNF $\alpha$  priming with the mechanism of action potentially mediated, at least in part, through increased levels of PEDF and VEGF-AA.

**Keywords:** exosomes, extracellular vesicles, TNF $\alpha$ , mesenchymal stem cells, glaucoma, priming, retinal ganglion cell

The retina is integral to transforming light information to an electrochemical signal and propagating this signal to the brain. Retinal ganglion cells (RGCs) are the final stage in the phototransductive pathway of the retina, and their axons make up the optic nerve. RGCs are acutely susceptible to optic nerve injury, and their loss, triggered by trauma or the degenerative neuropathies such as glaucoma, is one of the leading causes of vision loss worldwide.<sup>1</sup> No neuroprotective treatments are currently available to prevent RGC degeneration and cell loss.

Bone marrow mesenchymal stem cells (MSCs), a self-renewing multipotent stem cell population, have demonstrated significant therapeutic efficacy in models of retinal trauma and disease.<sup>2</sup> Intravitreal injection of MSCs yields a significant neuroprotective and axogenic effect in animal models of glaucoma<sup>3,4</sup> and other forms of optic neuropathy.<sup>5–7</sup> Evidence strongly suggests that the mechanism of

action is paracrine mediated, dependent on the expansive secretome of MSCs, which consists of multiple neurotrophic factors (NTFs) and exosomes.

While there is strong evidence that MSCs exert a significant effect on the retina through their signaling cytokines,<sup>8,9</sup> signaling in the opposite direction (i.e., signaling from the injured retina onto MSCs) has not been well studied and remains poorly understood. It has been suggested that the expansive secretome of MSCs can be modulated by signaling molecules from the injured environment, activating or “priming” the MSCs and further upregulating their therapeutic potential. In retinal ischemia, where MSC conditioned medium provides a neuroprotective effect and can partially restore visual function when injected into the vitreous,<sup>10</sup> the effect was significantly greater when MSCs had been subjected to hypoxic conditions prior to conditioning of culture,<sup>11</sup> suggesting that they can enter a primed




FIGURE 1. Overview of the Experimental Design.

state in response to injury. Similar observations have been seen when treating an animal model of stroke with hypoxia-preconditioned MSCs.<sup>12</sup>

It is suggested that the inflammatory milieu is responsible for priming MSCs, and one candidate is tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), a proinflammatory cytokine that is expressed by retinal glia and whose receptor, TNF $\alpha$  receptor 1, is expressed by RGCs.<sup>13</sup> Retinal glial cells, when exposed to stressors simulating ischemia or ocular hypertension/glaucoma, upregulated and released TNF $\alpha$ .<sup>14–17</sup> This increased TNF $\alpha$  expression is at least partially responsible for RGC death, and administration of TNF $\alpha$  neutralizing antibodies reduced RGC apoptosis.<sup>18</sup> In rat<sup>16,19</sup> and mouse<sup>20</sup> models of ocular hypertension, significant elevations in retinal and optic nerve levels of TNF $\alpha$  were observed. In human patients with glaucoma, TNF $\alpha$  and TNF $\alpha$  receptor 1 were upregulated compared with age-matched normal donors.<sup>17,21,22</sup> Recently, chronic ocular hypertension was shown to induce Müller cells to upregulate mRNA and protein expression of TNF $\alpha$  via ephrinB/EphB and downstream PI3K/Akt signaling.<sup>14</sup>

Our most recent work has demonstrated that MSC-derived exosomes exert a significant neuroprotective effect on RGCs.<sup>23,24</sup> Exosomes are small extracellular vesicles that contain microRNA, mRNA, proteins, and lipids. There is still contention in the field on the appropriate terminology, whether they should be called exosomes or extracellular vesicles, with *exosomes* reserved for those preparations that have used extensive isolation and characterization steps.<sup>25</sup> We use the term *exosome* throughout this article. Recent studies have shown that their internal cargo, both mRNA and proteins, can be modulated by injury.<sup>26</sup> Exposure of endothelial cells to stressors such as hypoxia and inflammation led to significant changes in protein and mRNA abundance within subsequently isolated exosomes. The present study aimed to better understand the changes that MSC-derived exosomes undergo when exposed to the injured retinal environment and whether their therapeutic efficacy can be increased. We primed MSCs by pretreatment

with dissociated retinal cell culture conditioned medium or TNF $\alpha$ . Primary rat retinal cultures and human stem cell-derived retinal cultures were then treated with MSC conditioned medium or MSC exosomes. MSC-exosomal proteins were analyzed, comparing unprimed MSCs to primed MSCs.

## MATERIALS AND METHODS

All reagents were purchased from Sigma (Allentown, PA, USA) unless otherwise specified. See Figure 1 for an overview of the experimental design.

### MSC Cultures

Human MSCs (bone marrow derived) were purchased from Lonza (Walkersville, MD, USA) and represented pooled samples from three donors. CD29<sup>+</sup>/CD44<sup>+</sup>/CD73<sup>+</sup>/CD90<sup>+</sup>/CD45<sup>−</sup> (confirmed by supplier) MSCs were seeded into T25 or T75 flasks, in a total volume of 5 mL or 15 mL Dulbecco's modified Eagle's medium (DMEM), respectively, containing 1% penicillin/streptomycin and 10% fetal bovine serum (Hyclone Laboratories, Logan, UT, USA) and at a quantity of  $1 \times 10^6$  cells and  $2 \times 10^6$  cells, respectively. Cultures were maintained at 37°C in 5% CO<sub>2</sub>, the supplemented medium was changed every three days, and the cells were passaged when 80% confluent using 0.05% trypsin/EDTA. For all experiments, MSCs were used at passages 2 to 5.

### Animals

Adult (10 weeks) female Sprague-Dawley rats weighing 170 to 200 g (Charles River, Wilmington, MA, USA) were housed under accordance with guidelines described in the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, using protocols approved by the National Eye Institute Committee on the Use and Care of Animals. These guidelines include conditions of 21°C and 55% humidity under a 12-hour light and dark cycle, food/water given ad

libitum, and being under constant supervision from trained staff. Animals were killed by rising concentrations of CO<sub>2</sub> before dissection of retinae.

### Retinal Cell Culture

Eight-well chamber slides (Thermo Fisher Scientific, Cincinnati, OH, USA) were precoated with 100 µg/mL poly-D-lysine for 60 minutes and then with 20 µg/mL laminin for 30 minutes. After culling and ocular dissection, the retinae of female Sprague-Dawley rats were minced in 1.25 mL papain (20 U/mL; Worthington Biochem, Lakewood, NJ, USA; as per manufacturer's instructions) containing 50 µg/mL DNase I (62.5 µL; Worthington Biochem) and incubated for 90 min at 37°C. The retinal cell suspension was centrifuged at 300 × *g* for 5 minutes and the pellet resuspended in 1.575 mL Earle's balanced salt solution (Worthington Biochem) containing 1.1 mg/mL reconstituted albumin ovomucoid inhibitor (150 µL; Worthington Biochem) and 56 µg/mL DNase I (75 µL). After adding to the top of 2.5 mL albumin ovomucoid inhibitor (10 mg/mL) to form a discontinuous density gradient, the retinal cell suspension was centrifuged at 70 × *g* for 6 minutes and the cell pellet resuspended in 1 mL of supplemented Neurobasal-A (25 mL Neurobasal-A; Life Technologies, Carlsbad, CA, USA), 1× concentration of B27 supplement (Life Technologies), 0.5 mM L-glutamine (62.5 µL; Thermo Fisher Scientific), and 50 µg/mL gentamycin (125 µL; Thermo Fisher Scientific). Retinal cells were then seeded into eight-well chamber slides at a concentration of 125,000 cells/well. After 72 hours in culture, retinal cell culture conditioned medium (from retinae collected from three animals) was collected to be used in MSC priming as below.

### MSC Priming

MSC cultures were primed by treating with retinal cell culture conditioned medium, prepared as above. Our previous studies have demonstrated that coculture of 50,000 MSCs with 125,000 dissociated retinal cells in 500 µL leads to significant neuroprotection and neuritogenesis.<sup>7,8</sup> Therefore, 500,000 MSCs in a T75 flask were primed by treatment with conditioned medium from 1,250,000 dissociated retinal cells. The retinal cell culture conditioned medium was concentrated using Amicon 10,000 Molecular weight filters (Millipore, Burlington, MA, USA) prior to treatment of MSCs. This approach concentrated the medium by approximately 10-fold, meaning instead of adding 4 mL of retinal conditioned medium (from 1,250,000 dissociated retinal cells) to a single T75 flask containing MSCs, we only needed to add 400 µL.

In place of retinal cell culture conditioned medium, MSCs were also primed with recombinant human TNFα (Gibco, Cincinnati, OH, USA; 10ng/mL) for 48 hours.<sup>27</sup> Retinal cell culture conditioned medium was also combined with the TNFα blocker, etanercept, at a concentration of 0.5 µg/mL according to previous dose-response studies *in vitro*.<sup>28</sup>

After culture in the priming medium (retinal conditioned medium or TNFα) for 48 hours, MSCs were washed in PBS three times, passaged, and grown in fresh DMEM containing 10% exosome depleted serum. After a further 48 hours in culture, MSC division rate was calculated and conditioned medium was collected (from three separate cultures) for the Luminex assay, exosome isolation, and assessment of neuroprotective/neuritogenic efficacy in retinal cultures.

**TABLE.** Antibodies Used in Immunocytochemistry (ICC) and Western Blot (WB)

Antigen	Dilution	Supplier	Catalogue No.
βIII-Tubulin	1:500 (ICC)	Sigma	#T-8660
Syntenin 1	1:1000 (WB)	Abcam	#Ab133267
CD63	1:1000 (WB)	System Bio	#Exoab-CD63-A1
ApoA1	1:1000 (WB)	Abcam	#ab7613
ApoB	1:1000 (WB)	Abcam	#ab20737
HSC70	1:5000 (WB)	Santa Cruz	#sc-7298
Mouse IgG HRP	1:2000 (WB)	GE Healthcare	#NA-931
Mouse IgG 488	1:400 (ICC)	Thermo Fisher	#A-11001
Mouse IgG HRP	1:2000 (WB)	GE Healthcare	#NA-931
Rabbit IgG HRP	1:10,000 (WB)	Cell Signalling	#7074

Horseradish peroxidase (HRP), XXX.

### Exosome Isolation

Exosomes were isolated from MSCs using ExoQuick-TC (System Biosciences, Mountain View, CA, USA) per the manufacturer's instructions. Briefly, conditioned medium was centrifuged at 3000 × *g* for 15 minutes before incubation with ExoQuick reagent overnight at 4°C (1:10 ratio with medium). The solution was centrifuged at 1500 × *g* for 15 minutes a final time before resuspension of exosome pellet in sterile PBS. The exosome preparation was then passed through a 0.22-µm filter to remove large microvesicles and apoptotic bodies. Exosomes were characterized via Western blot by their positive staining for the exosome markers Syntenin 1 and CD63 and negative staining for high/low-density lipoprotein markers ApoA1 and ApoB.<sup>24</sup> Briefly, exosomes were lysed in passive lysis buffer (Promega, Madison, WI, USA; #E1531) and protein samples (20 µg) were separated on 4% to 12% Bis-Tris protein gels at 150 V for 40 minutes. After transfer to polyvinylidene fluoride membranes and blocking in 10% Western blot blocking buffer (Roche, Basel, Switzerland) in Tris-buffered saline (TBS), proteins were stained overnight in primary antibody (Table) diluted in TBS. Samples were washed 3 × 5 minutes in Tris-buffered saline Tween (TBST), stained for 1 hour with secondary antibody (Table) in TBS, and washed 3 × 5 minutes in TBST before detection with Immobilon ECL reagents (Millipore, Burlington, MA, USA). Densitometry of Western blot bands was analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA) as previously reported.<sup>24</sup> All exosomes samples used in the study comprised exosomes pooled from three MSC donors.

The concentration and size distribution of exosomes were characterized using a NanoSight LM10 instrument (Malvern, Worcester, MA, USA), equipped with a 405-nm LM12 module and EM-CCD camera (DL-658-OEM-630; Andor, Concord, MA, USA). Three videos were captured per sample with a camera level of 10. Videos were analyzed with a detection threshold of 2, automatic blur size, and 12.9–13.1 pix maximum jump size. Slider gain was set to 80 and a total of 567 frames were taken.

### Retinal Culture Treatment

To assess neuroprotective and neuritogenic effects of MSCs on RGCs, retinal cells were isolated as above and cultured at a density of 125,000 cells/300 µL/well in eight-well chamber slides. Retinal cultures were treated with MSC conditioned medium (primed or unprimed) and incubated for 72 hours at 37°C before fixation and immunocytochemical



staining of RGCs with  $\beta$ III-tubulin as detailed below. MSC conditioned medium treatments were 50  $\mu$ L (concentrated using Amicon 10,000 Molecular weight filters) per well and derived from 50,000 MSCs over 48 hours. Selected cultures were treated with human recombinant Ciliary neurotrophic factor (CNTF) as a positive control (50 ng/mL). For this study, large spherical  $\beta$ III-tubulin<sup>+</sup> rat retinal cells,<sup>29</sup> which can be identified by preferential  $\beta$ III-tubulin staining intensity around the axonal base, are referred to as RGCs. Previous immunocytochemical analysis of these cultures in our laboratory demonstrates that 60% of these retinal cells are neurons (neurofilament<sup>+</sup>/ $\beta$ III-tubulin<sup>+</sup>), of which 10% are Thy1<sup>+</sup> RGCs and possess the unique  $\beta$ III-tubulin staining pattern described above.<sup>30</sup> Retinal cultures consisted of cultures from three different animals, three wells per animal.

### Human Stem Cell-Derived RGCs (hRGCs)

An H9-derived human embryonic stem cell line engineered such that tdTomato and mouse THY1.2 were knocked into the *POU4F2* (*BRN3B*) locus was differentiated into human RGCs (hRGCs) according to the published protocol.<sup>31,32</sup> Briefly, cells are plated and grown on Matrigel (Corning, NY, USA) coated plates in mTeSR medium (Stem Cell Technologies, Vancouver, Canada) supplemented with blebbistatin (5  $\mu$ M). Medium is switched on day 1 to retinal differentiation medium (RDM; DMEM/F12 + Neurobasal A medium [mixed 50:50], 1 $\times$  Glutamax, 1 $\times$  anti-anti, 1 $\times$  N2 supplement, and 1 $\times$  B27 supplement; Thermo Fisher Scientific) and cultured in this medium up until day 40. Small molecules are added as follows: days 1 to 6, dorsomorphin (1  $\mu$ M), inducer of definitive endoderm 2 (2.5  $\mu$ M; Stem Cell Technologies), forskolin (25  $\mu$ M), and nicotinamide (10  $\mu$ M); days 6 to 10, forskolin and nicotinamide; days 10 to 18, forskolin; days 18 to 30, forskolin and N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) (10  $\mu$ M); and days 30 to 40, RDM alone. Note that the cultures contain hRGCs as well as other retinal cells but are called hRGCs for the sake of brevity.

Unlike adult rodent-derived RGC cultures that degenerate in culture without intervention, hRGCs do not degenerate unless triggered to do so. To induce stress, damage, and subsequent death, hRGCs were treated with 1  $\mu$ M colchicine as previously described.<sup>32</sup> Exosome treatment was given at the same time, and after 48 hours, cells were fixed as detailed below without the need for immunocytochemical staining. Three wells were used per treatment group and were repeated three times on separate days and with separate cultures.

### Immunocytochemistry

Retinal cells were fixed in 4% paraformaldehyde in PBS for 10 minutes, washed for 3  $\times$  10 minutes in PBS, blocked in blocking solution (3% bovine serum albumin [g/mL], 0.1% Triton X-100 in PBS) for 20 minutes, and incubated with primary antibody (Table) diluted at 1:500 in antibody diluting buffer (ADB; 0.5% bovine serum albumin, 0.3% Tween-20 in PBS) for 1 hour at room temperature. Cells were then washed for 3  $\times$  10 minutes in PBS, incubated with the secondary antibody (Table) diluted in ADB for 1 hour at room temperature, washed for 3  $\times$  10 minutes in PBS, mounted in Vectorshield mounting medium containing DAPI (Vector Laboratories, Peterborough, UK), and stored at 4°C.

### Enzyme-Linked Immunosorbent Assay (ELISA)

To quantify the amount of TNF $\alpha$  released by cultured retina, conditioned medium from three separate cultures/animals was collected and assayed using a duoset ELISA kit according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). Briefly, a standard curve was constructed using TNF $\alpha$  standards and test samples of conditioned medium at increasing dilutions, run in duplicate with TNF $\alpha$  concentrations extrapolated from the standard curve.

### Multiplex Bead Immunoassay (Luminex)

Conditioned media from three separate cultures of MSCs and retina were analyzed using a neurotrophic multiplex Luminex kit (Thermo Fisher Scientific) according to the manufacturer's instructions and using the same principles described in the ELISA section. Assays were run using a Luminex-100 system (Luminex, Austin, TX, USA).

### Microscopy and Analysis

Retinal cultures were imaged using an LSM700 laser scanning confocal microscope (Carl Zeiss, Inc., Thornwood, NY, USA). For rat retinal cultures, the entire eight-well chamber was imaged and the number of  $\beta$ III-tubulin<sup>+</sup> RGC/RGC with neurites was quantified. For hRGC cultures, 1-mm<sup>2</sup> scans were collected and the number of BRN3B<sup>+</sup> RGCs was quantified. Counts were conducted manually by an individual masked to the treatment groups. All cell cultures (rat and human) were performed both in triplicate and three separate times ( $n = 3$ ).


### Statistics

Animal numbers were determined beforehand using a power calculation (Gpower). All statistical tests were performed using SPSS 17.0 (IBM SPSS, Inc., Chicago, IL, USA) and data presented as mean  $\pm$  standard error of the mean (SEM) with graphs constructed using SigmaPlot (San Jose, CA, USA). The Shapiro-Wilkes test was used to ensure all data were normally distributed before parametric testing using a one-way analysis of variance (ANOVA) with a Tukey post hoc test. Statistical differences were considered significant at  $P$  values  $< 0.05$ . For the quantitative real-time polymerase chain reaction (qRT)-PCR, data were compared by a Student's  $t$ -test and statistical significance set at  $P < 0.001$ .

## RESULTS

### MSC Conditioned Medium Is Neuroprotective in Adult Rat Retinal Cultures, but Only When Primed

We first determined the neuroprotective and neuritogenic properties of retinal cell culture and TNF $\alpha$ -primed MSC conditioned medium in freshly isolated rat retinal cells. In untreated controls,  $92 \pm 12$  (mean  $\pm$  SEM) RGCs survived with  $36.7 \pm 1.5$  RGCs containing neurites (Figs. 2A, 2E, 2F). Retinal cells cultured with the positive control CNTF showed  $276.3 \pm 12.7$  surviving RGCs and  $113.7 \pm 5.7$  RGCs with neurites (Figs. 2B, 2E, 2F) while treatment of retinal cells with unprimed MSC conditioned medium promoted the survival of  $110.7 \pm 10.7$  RGCs and  $58.3 \pm 16.6$  RGCs with neurites (Figs. 2C, 2E, 2F). However, treatment of retinal cells with retinal cell culture-primed MSC conditioned




**FIGURE 2.** MSC conditioned medium treatment of heterogenous retinal cultures. Heterogenous adult rat retinal cultures were left for three days either untreated (negative control; **A**), treated with CNTF (positive control; **B**), treated with MSC conditioned medium (**C**), treated with primed MSC conditioned medium without (**D**) or with etanercept (TNF $\alpha$  blocker) added during priming, or treated with TNF $\alpha$  primed MSC conditioned medium without or with etanercept added during priming (scale bar: 50  $\mu$ m). The number of RGCs (**E**), denoted by their asymmetrical  $\beta$ III-tubulin staining, and the number of RGCs with neurites (**F**) were quantified ( $n = 3$ ). Asterisks indicate a significant increase in RGC neuroprotection/neuritogenesis in comparison to untreated control/unprimed MSC conditioned medium ( $P < 0.05$ ) and includes CNTF treatment and primed MSC (via retinal medium or TNF $\alpha$ ) conditioned medium treatment.

medium (referred to simply as “primed MSC conditioned medium”) elicited significant neuroprotection ( $255 \pm 20.5$  RGCs) and neuritogenesis ( $115 \pm 25.9$  RGCs with neurites) (Figs. 2D, 2E, 2F) compared with unprimed MSC conditioned medium and untreated controls (Fig. 2). Significant neuroprotection and neuritogenesis, similar to primed MSC conditioned medium, was also achieved after treatment with conditioned medium from MSCs primed with TNF $\alpha$  ( $285.3 \pm 8.5$  RGCs and  $113.7 \pm 5.7$  RGCs with neurites, respectively) (Figs. 2E, 2F), and both priming methods were equivalently neuroprotective and neuritogenic as CNTF-treated positive control cultures. If etanercept, a potent blocker of TNF $\alpha$ , was included in the MSC culture during priming, the primed MSC conditioned medium (primed via treatment with rat retinal cultures or TNF $\alpha$ ) no longer elicited neuroprotection ( $90.7 \pm 3.8$  and  $100.7 \pm 10.8$  RGCs, respectively) or neuritogenesis ( $42 \pm 5.6$  and  $43.7 \pm 9.5$  RGCs with neurites, respectively) (Figs. 2E, 2F). These results demonstrate that both primed MSC conditioned medium and MSC conditioned medium primed with TNF $\alpha$  cause significant RGC protection and neurite outgrowth. In addition, the ablation of priming by etanercept demonstrates that retinal conditioned medium primed MSCs primarily through TNF $\alpha$ .

### MSC Exosomes Are Neuroprotective in hRGC Cultures and More Effective After Priming

We next determined if MSC exosomes were neuroprotective to hRGCs and whether priming with TNF $\alpha$  potentiated the neuroprotective effects. Whereas rodent retinal cultures degenerate spontaneously in culture, hRGCs require colchicine to trigger their degeneration.<sup>31,32</sup> In untreated cells + vehicle (PBS), abundant BRN3B<sup>+</sup> hRGCs were detected in culture (Figs. 3A, 3F) while the addition of colchicine to hRGC cultures caused an approximate 80% loss of hRGCs ( $107.5 \pm 9.3$  hRGCs; Figs. 3B, 3F) compared with uninjured cultures ( $539 \pm 39$  hRGCs; Figs. 3A, 3F). Treatment with MSC exosomes led to significant hRGC neuroprotection ( $208.1 \pm 14.2$  hRGCs; Figs. 3D, 3F) compared with untreated, colchicine-injured cultures and was equivalent to CNTF-treated positive control cultures ( $224.8 \pm 60.7$  hRGCs; Figs. 3C, 3F). Moreover, treatment with TNF $\alpha$ -primed MSC exosomes led to a significantly enhanced neuroprotective effect ( $355.7 \pm 7.3$  hRGCs) compared with MSC exosome treatment (Figs. 3E, 3F). These results demonstrate that MSC exosomes and TNF $\alpha$ -primed MSC exosomes provide significant neuroprotection to hRGCs cultured in the presence of “injury-inducing” colchicine.



**FIGURE 3.** Exosome treatment of heterogeneous human stem cell-derived retinal cultures. Heterogeneous retinal cultures derived from human stem cells were left uninjured/untreated (**A**), injured with colchicine but untreated (negative control; **B**), injured with colchicine/treated with CNTF (positive control; **C**), injured with colchicine/treated with MSC exosomes (**D**), or injured with colchicine/treated with TNF $\alpha$  primed MSC exosomes (**E**; scale bar: 250  $\mu$ m). The number of RGCs (**F**), identified by the Brn3b expression, were quantified ( $n = 3$ ). Asterisks indicate significant difference from untreated/colchicine-injured control at  $P < 0.05$ ). Asterisks also indicate a significant increase in RGC neuroprotection in comparison to untreated/colchicine-injured control ( $P < 0.05$ ) and include CNTF treatment, exosome treatment, and TNF $\alpha$  primed exosome treatment. Furthermore, significant difference was also observed between exosome treatment and TNF $\alpha$  primed exosome treatment (double asterisks).

### Retinal Conditioned Medium, Used to Prime MSCs, Contains TNF $\alpha$

With retinal conditioned medium reliably priming MSC and etanercept, a TNF $\alpha$  blocker, inhibiting priming, we next sought to confirm that conditioned medium from retinal cell cultures contained TNF $\alpha$ . TNF $\alpha$  was absent from supplemented Neurobasal-A, but significant concentrations were observed after retinal cell culture conditioning for 24 hours ( $518 \pm 109.9$  pg/mL) and 48 hours ( $1175.4 \pm 154.9$  pg/mL; Fig. 4). These results demonstrate that significant titers of TNF $\alpha$  were present in conditioned medium from retinal cell cultures.

### Priming Had No Effect on Division/Exosome Secretion Rate


We then investigated if priming MSCs with TNF $\alpha$  altered their division rate or secretion of exosomes. MSC divi-

sion rate following TNF $\alpha$  priming ( $0.76 \pm 0.23$  divisions/24 hours) was not significantly different from the division rate of unprimed MSCs ( $0.79 \pm 0.21$  divisions/24 hours; Fig. 5A). MSC exosome secretion rate following TNF $\alpha$  priming ( $1.88 \times 10^6 \pm 5.34 \times 10^5$  exosomes/100,000 cells/24 hours) trended toward but was not significantly higher than the exosome secretion rate of unprimed MSCs ( $1.25 \times 10^6 \pm 2.75 \times 10^5$  exosomes/100,000 cells/24 hours; Fig. 5B). These results showed that MSC division rate and secretion of exosomes were unaffected by priming.

### Priming MSCs Significantly Increases Exosomal PEDF, VEGF-A, and Platelet-derived growth factor (PDGF)-AA

We next determined the abundance of a number of NTFs in exosome preparations from MSC conditioned medium, retinal cell culture conditioned medium, and primed MSC





**FIGURE 4.** TNFα secretion by heterogeneous retinal culture. Retinal culture conditioned medium, collected after 24 or 48 hours in culture (or unconditioned controls), was assayed using a TNFα ELISA ( $n = 3$ ; black lines indicate significant difference at  $P < 0.05$ ).


conditioned medium. We observed that PEDF abundance was significantly enhanced in primed MSC conditioned medium and TNFα primed conditioned medium ( $3693 \pm 232$  pg/mL and  $4469 \pm 261$  pg/mL, respectively) compared with unprimed MSCs ( $1408 \pm 93$  pg/mL; Fig. 6). VEGF-A abundance was also significantly enhanced in MSC conditioned medium and TNFα primed conditioned medium ( $1263 \pm 38$  pg/mL and  $1063 \pm 40$  pg/mL, respectively) compared with unprimed MSCs ( $514 \pm 37$  pg/mL). PDGF-AA abundance was significantly enhanced after priming ( $5.74 \pm 0.65$  pg/mL) but not after TNFα priming ( $3.15 \pm 0.49$  pg/mL) compared with unprimed MSCs ( $2.86 \pm 0.69$  pg/mL). Brain-derived neurotrophic factor (BDNF), VEGF-C, NT-4, FGF, and PDGF-CC were detectable but not significantly increased after priming/TNFα priming. Beta-NGF, PDGF-DD, PDGF-BB, Epidermal growth factor (EGF), VEGF-D, and PDGF-AB were possible analytes in the present assay but were not detected.

## DISCUSSION

The present study demonstrates that MSCs are receptive to priming following their introduction to an injured environment. In the case of the injured retina, MSCs are primed due to the release of TNFα. After priming, MSCs exert a significantly greater neuroprotective effect on injured RGCs, both rat and human derived. Congruent with our previous work, this effect is paracrine mediated,<sup>8</sup> likely through their released exosomes.<sup>33</sup> The augmented effect TNFα priming afforded MSC exosomes possibly involves an increase in exosomal NTFs.


TNFα acts through two receptors, TNF receptors 1 and 2, with receptor 2 being the likely candidate for its actions on neural cells.<sup>34</sup> Previous work has demonstrated that stimulation of MSCs by TNFα significantly upregulated production of NTFs, including VEGF, Hepatocyte growth factor (HGF), and Insulin-like growth factor (IGF).<sup>35</sup> Mitogen-activated protein kinase (MAPK) inhibitors decreased the production of these NTFs while they had no effect on baseline secretion, suggesting the upregulated secretion is a distinct mechanism. In a separate study, MSCs exposed to either hypoxic conditions or TNFα are activated through the NF-κB pathway and upregulate their secretion of several NTFs, including VEGF, FGF2, IGF-1, and HGF.<sup>36</sup> As well as secretion of NTFs, migration into injured tissue is an important property integral to the regenerative potential of MSCs. Treatment of MSCs with TNFα increased their invasion and migration through the extracellular matrix, attributed partially to the upregulation of intracellular adhesion molecule 1<sup>37</sup> and vascular cell adhesion protein 1.<sup>38</sup> In the present study, we demonstrated that retinal conditioned medium was ineffective at priming MSCs if etanercept, a TNFα inhibitor, was included, suggesting TNFα is a critical mediator in priming MSCs in this model.

Both PEDF and VEGF-AA, which were found to be significantly upregulated after TNFα priming of MSCs, are known neuroprotective agents for injured RGCs. Müller cells exert a neuroprotective effect on RGCs through the secretion of PEDF,<sup>39</sup> while delivery of PEDF into retinal cultures or rat eyes after optic nerve crush leads to significant RGC neuroprotection.<sup>40</sup> Delivery of VEGF into ocular hypertensive eyes leads to significant RGC neuroprotection while also upregulating PEDF.<sup>41</sup> A separate study in an ocular



**FIGURE 5.** Division and exosome secretion rate of primed MSCs. (A) The mean number of divisions of unprimed MSCs and those primed by TNFα. (B) The mean number of exosomes secreted by unprimed MSCs and those primed by TNFα ( $n = 3$ , no significant differences observed at  $P > 0.05$ ).





**FIGURE 6.** Luminex analysis of primed MSC protein secretome. Luminex analysis was performed on control MSC growth media, control retinal conditioned medium, unprimed MSC conditioned medium, primed MSC conditioned medium, and TNF $\alpha$  primed conditioned medium ( $n = 3$ ; black lines indicate significant differences between primed and unprimed at  $P < 0.05$ ). Beta-NGF, PDGF-DD, PDGF-BB, EGF, VEGF-D, and PDGF-AB were not detected.

hypertensive model demonstrated that VEGF-A promoted RGC neuroprotection via direct activation of the VEGF receptor 2 and signaling through the phosphoinositide-3-kinase/Akt pathway.<sup>42</sup> The same group showed that treating the same primary retinal cultures used in this study with VEGF-A elicited 50% more RGC neuroprotection than untreated controls. While comparative analysis is difficult as the referenced study used hypoxia to injure the cultured RGCs, exosomes appear to be more efficacious, likely due to their cargo containing multiple NTFs. In comparison to VEGF, PEDF appears to act, at least partially, through retinal glia, leading to suppression of RGC caspase 2.<sup>43</sup> Treatment of RGC cultures with PEDF leads to a 63% increase in RGC survival in comparison to untreated cultures, which, similar to VEGF-A, cannot account for the full neuroprotective effect elicited by exosomes. PDGF-AA is also a potent neuroprotective for RGCs and an integral component of the neuroprotective secretome of MSCs.<sup>9</sup> Interestingly, while PDGF-AA abundance in or associated with exosomes was upregulated following MSC priming with retinal conditioned medium, this was not seen when MSCs were primed with TNF $\alpha$ . While the present study focused on TNF $\alpha$ , it is apparent that other injury-associated cytokines are involved in the priming of MSCs. While these NTFs were identified in our exosome samples, it is possible they were not in the cargo but rather externally associated with the exosomes. A previous study performing proteomic analysis of extracellular vesicles demonstrated the presence of PEDF, with the authors suggesting that the protein is extracellular and associated with the exosome.<sup>44</sup> Further study is required to confirm the importance of these cytokines in the improved neuroprotective efficacy of primed MSCs.

We tested our samples in two in vitro models of RGC death. The first was a primary culture of adult rat RGCs. We have already demonstrated the neuroprotective efficacy of MSC exosomes in this model,<sup>33</sup> and thus, it served as a reliable system with which to compare the improved efficacy of primed MSC exosomes/conditioned medium. The second in vitro model was hRGCs derived from human stem cell cultures.<sup>31,32</sup> To our knowledge, this is the first time exosomes have been used as a therapeutic on hRGCs, and our results not only reinforce our previous findings in rodent models but also add credibility to the improved therapeutic efficacy after priming.

In conclusion, the present study demonstrated the feasibility and ease by which the efficacy of MSCs and their exosomes can be improved. TNF $\alpha$  is one such priming candidate, and the effects appear to involve the upregulation of neurotrophic proteins that are released in, or associated with, exosomes. Finally, we build upon the established literature demonstrating a neuroprotective efficacy of MSC exosomes by showing that their potential also extends to human retina. Future studies will be directed toward improving exosomes' efficacy while ensuring their safety and tolerance, having translation into patients as the rapidly approaching goal.

### Acknowledgments

Supported by the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No. 749346 and the Intramural Research Programs of the National Eye Institute.

Disclosure: **B. Mead**, None; **X. Chamling**, None; **D.J. Zack**, None; **Z. Ahmed**, None; **S. Tomarev**, None

### References

1. Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040. *Ophthalmology*. 2014;121:2081–2090.
2. Mead B, Berry M, Logan A, Scott RAH, Leadbeater W, Scheven BA. Stem cell treatment of degenerative eye disease. *Stem Cell Res*. 2015;14:243–257.
3. Mead B, Hill LJ, Blanch RJ, et al. Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma. *Cytotherapy*. 2016;18:487–496.
4. Johnson TV, Bull ND, Hunt DP, Marina N, Tomarev SI, Martin KR. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. *Invest Ophthalmol Vis Sci*. 2010;51:2051–2059.
5. Mesentier-Louro LA, Zaverucha-do-Valle C, da Silva-Junior AJ, et al. Distribution of mesenchymal stem cells and effects on neuronal survival and axon regeneration after optic nerve crush and cell therapy. *PLoS One*. 2014;9:e110722.
6. Tan HB, Kang X, Lu SH, Liu L. The therapeutic effects of bone marrow mesenchymal stem cells after optic nerve damage in the adult rat. *Clin Interv Aging*. 2015;10:487–490.
7. Mead B, Logan A, Berry M, Leadbeater W, Scheven BA. Intravitreally transplanted dental pulp stem cells promote neuroprotection and axon regeneration of retinal ganglion cells after optic nerve injury. *Invest Ophthalmol Vis Sci*. 2013;54:7544–7556.
8. Mead B, Logan A, Berry M, Leadbeater W, Scheven BA. Paracrine-mediated neuroprotection and neurogenesis of axotomized retinal ganglion cells by human dental pulp stem cells: comparison with human bone marrow and adipose-derived mesenchymal stem cells. *PLoS One*. 2014;9:e109305.
9. Johnson TV, Dekorver NW, Levasseur VA, et al. Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome. *Brain*. 2014;137(pt 2):503–519.
10. Dreixler JC, Poston JN, Balyasnikova I, et al. Delayed administration of bone marrow mesenchymal stem cell conditioned medium significantly improves outcome after retinal ischemia in rats. *Invest Ophthalmol Vis Sci*. 2014;55:3785–3796.
11. Roth S, Dreixler JC, Mathew B, et al. Hypoxic-preconditioned bone marrow stem cell medium significantly improves outcome after retinal ischemia in rats. *Invest Ophthalmol Vis Sci*. 2016;57:3522–3532.
12. Wei N, Yu SP, Gu XH, et al. Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice. *Cell Transplant*. 2013;22:977–991.
13. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. *Prog Brain Res*. 2008;173:409–421.
14. Liu S-T, Zhong S-M, Li X-Y, et al. EphrinB/EphB forward signaling in Müller cells causes apoptosis of retinal ganglion cells by increasing tumor necrosis factor alpha production in rat experimental glaucomatous model. *Acta Neuropathol Commun*. 2018;6:111.
15. Gesslein B, Håkansson G, Gustafsson L, Ekström P, Malmström M. Tumor necrosis factor and its receptors in the neuroretina and retinal vasculature after ischemia-reperfusion injury in the pig retina. *Mol Vision*. 2010;16:2317–2327.
16. Cueva Vargas JL, Osswald IK, Unsain N, et al. Soluble tumor necrosis factor alpha promotes retinal ganglion cell death in glaucoma via calcium-permeable AMPA receptor activation. *J Neurosci*. 2015;35:12088–12102.

17. Tezel Gln, Li LY, Patil RV, Wax MB. TNF- $\alpha$  and TNF- $\alpha$  receptor-1 in the retina of normal and glaucomatous eyes. *Invest Ophthalmol Vis Sci*. 2001;42:1787–1794.
18. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci*. 2011;108:5003–5008.
19. Sapienza A, Raveu A-L, Reboussin E, et al. Bilateral neuroinflammatory processes in visual pathways induced by unilateral ocular hypertension in the rat. *J Neuroinflamm*. 2016;13:44.
20. Tezel G, Yang X, Yang J, Wax MB. Role of tumor necrosis factor receptor-1 in the death of retinal ganglion cells following optic nerve crush injury in mice. *Brain Res*. 2004;996:202–212.
21. Sawada H, Fukuchi T, Tanaka T, Abe H. Tumor necrosis factor- $\alpha$  concentrations in the aqueous humor of patients with glaucoma. *Invest Ophthalmol Vis Sci*. 2010;51:903–906.
22. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor  $\alpha$  in glaucomatous optic nerve head. *JAMA Ophthalmol*. 2000;118:666–673.
23. Mead B, Ahmed Z, Tomarev S. Mesenchymal stem cell-derived small extracellular vesicles promote neuroprotection in a genetic DBA/2J mouse model of glaucoma neuroprotection by exosomes in DBA/2J mice. *Invest Ophthalmol Vis Sci*. 2018;59:5473–5480.
24. Mead B, Amaral J, Tomarev S. Mesenchymal stem cell-derived small extracellular vesicles promote neuroprotection in rodent models of glaucoma. *Invest Ophthalmol Vis Sci*. 2018;59:702–714.
25. Witwer KW, Théry C. Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature. *J Extracell Vesicles*. 2019;8:1648167.
26. de Jong OG, Verhaar MC, Chen Y, et al. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. *J Extracell Vesicles*. 2012;1.
27. Kwon YW, Heo SC, Jeong GO, et al. Tumor necrosis factor- $\alpha$ -activated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. *Biochim Biophys Acta*. 2013;1832:2136–2144.
28. Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor  $\alpha$ , interferon- $\gamma$  and GM-CSF in in vivo activated intestinal T lymphocyte cultures. *Cytokine*. 2003;23:76–85.
29. Sullivan KF. Structure and utilization of tubulin isotypes. *Annu Rev Cell Biol*. 1988;4:687–716.
30. Suggate EL, Ahmed Z, Read ML, et al. Optimisation of siRNA-mediated RhoA silencing in neuronal cultures. *Mol Cell Neurosci*. 2009;40:451–462.
31. Sluch VM, Davis C-hO, Ranganathan V, et al. Differentiation of human ESCs to retinal ganglion cells using a CRISPR engineered reporter cell line. *Sci Rep*. 2015;5:16595.
32. Sluch VM, Chamling X, Liu MM, et al. Enhanced stem cell differentiation and immunopurification of genome engineered human retinal ganglion cells. *Stem Cells Transl Med*. 2017;6:1972–1986.
33. Mead B, Tomarev S. BMSC-derived exosomes promote survival of retinal ganglion cells through miRNA-dependent mechanisms. *Stem Cells Transl Med*. 2017;6:1273–1285.
34. Yan L, Zheng D, Xu RH. Critical role of tumor necrosis factor signaling in mesenchymal stem cell-based therapy for autoimmune and inflammatory diseases. *Front Immunol*. 2018;9:1658.
35. Wang M, Crisostomo PR, Herring C, Meldrum KK, Meldrum DR. Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. *Am J Physiol Regul Integr Comp Physiol*. 2006;291:R880–R884.
36. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, Meldrum DR. Human mesenchymal stem cells stimulated by TNF- $\alpha$ , LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. *Am J Physiol Cell Physiol*. 2008;294:C675–C682.
37. Fu X, Han B, Cai S, Lei Y, Sun T, Sheng Z. Migration of bone marrow-derived mesenchymal stem cells induced by tumor necrosis factor- $\alpha$  and its possible role in wound healing. *Wound Repair Regen*. 2009;17:185–191.
38. Xiao Q, Wang SK, Tian H, et al. TNF- $\alpha$  increases bone marrow mesenchymal stem cell migration to ischemic tissues. *Cell Biochem Biophys*. 2012;62:409–414.
39. Eichler W, Savković-Cvijić H, Bürger S, et al. Müller cell-derived PEDF mediates neuroprotection via STAT3 activation. *Cell Physiol Biochem*. 2017;44:1411–1424.
40. Vigneswara V, Berry M, Logan A, Ahmed Z. Pigment epithelium-derived factor is retinal ganglion cell neuroprotective and axogenic after optic nerve crush injury. *Invest Ophthalmol Vis Sci*. 2013;54:2624–2633.
41. Lv B, Wang R, Gao X, Dong X, Ji X. Effect of vascular endothelial growth factor on retinal ganglion cells of rats with chronic intraocular hypertension. *Int J Clin Exp Pathol*. 2014;7:5717–5724.
42. Foxton RH, Finkelstein A, Vijay S, et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. *Am J Pathol*. 2013;182:1379–1390.
43. Vigneswara V, Ahmed Z. Pigment epithelium-derived factor mediates retinal ganglion cell neuroprotection by suppression of caspase-2. *Cell Death Dis*. 2019;10:102.
44. Kowal J, Arras G, Colombo M, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc Natl Acad Sci USA*. 2016;113:E968–E977.